ARE YOUR CONTRIBUTIONS BEING OVERLOOKED? Don’t let the millions of dollars in free product you donate each year go unnoticed. Inform key state and federal decision makers such as governors, senators, representatives, and other government officials about your patient assistance program (PAP) contributions. PAREXEL’s report is a powerful public relations tool that utilizes hard data to report detailed statistics on your assistance programs such as the number of physicians utilizing your indigent programs, the number of patients served through your programs, the number of prescriptions filled, and the total dollar value of your drug donations. This report has been proven invaluable as:
• An effective tool for internal government affairs or pubic relations staff in communicating with government, public officials, lobbyists and the media. • A way to determine the key districts/regions on which to focus sales efforts, and to assist in determining future PAP strategy. • An easy means of reporting consolidated data to organizations such as the Pharmaceutical Researchers and Manufacturers of America (PhRMA).
PAREXEL can also provide analysis of the report, such as a comparison of variations in utilization rates among the 50 states and compare PAP trends with current Medicaid and other public benefit trends to determine the impact Medicaid and alternative benefits are having on PAP enrollment.
If you are interested in subscribing to or learning more about this report, please contact ChristyMcMann at christy.mcmann@parexel.com
President Bush has proposed a $60 billion cut in Medicaid services over the next decade. How will that affect your customers? Keep abreast of the latest state Medicaid managed care activities with The Quarterly Medicaid Managed Care Tracking Report, a subscription service that provides longitudinal tracking of state Medicaid recipients' participation in Medicaid managed care programs that include the pharmacy benefit within their overall capitation rates. Subscription to this service provides a quarterly “snapshot” of Medicaid managed care enrollment trends in all 50 states and the District of Columbia -- information which will assist the subscriber in making critical decisions about product/market development in a constantly evolving health care marketplace. This information includes: • Medicaid managed care enrollment data, either by eligibility, geographic region, or plan. • Total of state's Medicaid population. • State pharmacy benefit administration (carve-in, carve-out). • HIV drug benefit administration (carve-out, partial carve-out, capitation rate adjustments) • Name of contracting managed care plans that include the pharmacy benefit. If you are interested in subscribing to or learning more about this report, please contact Christy McMann at christy.mcmann@parexel.com
_________________________
HEALTH POLICY AND PAYER RELATIONS
As a new drug, biotechnology, or medical device product approaches market launch, its manufacturer must possess a clear, in-depth understanding of the public and private reimbursement environment that the product will face.
As the leader in developing solutions for complex health policy and reimbursement issues facing manufacturers, PAREXEL's Health Policy and Payer Relations team provides our industry clients with a range of services to remove barriers to product acceptance, further appropriate patient access, and demonstrate a product’s value. We also distill health policy developments into their essential elements and provide strategic recommendations to our clients on how broad healthcare issues will impact the industry.
Through our offices in metropolitan Washington, DC, we interact with key legislators, senior healthcare regulators, national association executives, and other public policy leaders to guide our clients through the complex and ever-changing healthcare landscape. Additionally, we work closely with PAREXEL’s co-located Reimbursement HELPlines
, Patient Assistance Programs, and Phase IV Program Coordinating Centers to provide our clients a single point of contact for strategic health policy and reimbursement solutions.
For more information on PAREXEL's health policy services, please click here.
For more information on PAREXEL's payer relations services, please click here.
_________________________
PAREXEL INTERNATIONAL CORPORATION
Founded in 1983 as a regulatory consulting firm serving the healthcare services industry, PAREXEL International Corporation (PAREXEL) is today one of the largest contract research organizations (CRO) in the world. For over two decades, PAREXEL has played a key role in the pharmaceutical, biotechnology, and medical device industries by partnering with clients to accelerate time-to-market, control development costs, reduce risk, and maximize return on investment.
As one of the largest pharmaceutical services companies in the world, PAREXEL delivers a full range of services and solutions through its offices in 36 countries. Our clients are the industry leaders -- a recent study showed that PAREXEL works for eight of the top 10 pharmaceutical companies in the world. For more information, please visit the PAREXEL Web site.
